Skip to Content

Are you based in North America? If yes, switch to our North American website →

IGH/cMYC(MYC) Plus Translocation, Dual Fusion

Applications
haematology
Catalogue Numbers
LPH 076-S (5 tests)
LPH 076 (10 tests)

Probe Specification

  • cMYC, 8q24.21, Red
  • IGH, 14q32.33, Green

The IGH/cMYC Plus product consists of probes, labelled in green, proximal to the Constant, and within the Variable segment of the IGH region, and cMYC probes, labelled in red. The cMYC probe mix contains a 220kb probe centromeric to the cMYC (MYC) gene and a second probe covering the 186kb region telomeric to the cMYC gene, including the D8S1644 marker.

Probe Information

The t(8;14)(q24;q32) translocation involving the IGH (immunoglobulin heavy locus) gene at 14q32.33 and the MYC (MYC proto-oncogene, bHLH transcription factor) oncogene at 8q24 is a recognised recurrent abnormality commonly seen in patients with B-cell malignancy.

IGH-MYC rearrangements are detected in up to 85% of cases of Burkitt lymphoma at diagnosis1. They are also seen in diffuse large B-cell lymphoma (DLBCL)2, multiple myeloma and plasmablastic lymphoma3,4.

In an IGH-MYC rearrangement the translocation breakpoints on chromosome 14 are clustered to a narrow region 5' to the intron enhancer of the immunoglobulin heavy chain, whereas the breakpoints on chromosome 8 can occur more than 340kb upstream of MYC, with no preferential site5. The translocation brings MYC into close proximity to the IGH enhancer and results in the up-regulation of MYC. Over-expression of the transcription factor stimulates gene amplification, resulting in uncontrolled cell proliferation6.

In our hands, Cytocell FISH probes, have proven to be of the highest quality with bright, easy to interpret signals, thus providing confidence in our results. Cytocell’s customer support is outstanding, as their staff are extremely knowledgeable and truly care about their customers and their customers’ needs. Jennie Thurston, Director of Cytogenetics at Carolinas Pathology Group

References

  1. Perkins AS, Friedberg JW. Hematology Am Soc Hematol Educ Program. 2008;341-8
  2. Ott G, et al., Blood. 2013 Dec 5;122(24):3884-91
  3. Walker BA, et al., Blood Cancer J. 2014;4(3):e191
  4. Elyamany G, et al., Adv Hematol 2015;2015:315289
  5. Joos et al., Human Molecular Genetics 1992;1(8):625-32
  6. Erikson J et al., Proc Natl Acad Sci USA 1983;80(3):820-4
  7. Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The AGT Cytogenetics Laboratory Manual. New Jersey: John Wiley & Sons Inc.
  8. Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.
  9. Wiktor AE, Dyke DLV, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, Dewald GW. Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genetics in Medicine. 2006;8(1):16–23.

Microscope Images

IGH cMYC (MYC) Plus Translocation Dual Fusion magnified
Area of Interest*
ALL, Lymphoma

Disclaimer

This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.

*Disease information supported by the literature and is not a reflection of the intended purpose of this product.